Fatima Cardoso mostly deals with Breast cancer, Internal medicine, Oncology, Cancer and Surgery. Her studies in Breast cancer integrate themes in fields like Gynecology and Clinical trial, Pathology. Her work investigates the relationship between Internal medicine and topics such as Gene expression profiling that intersect with problems in Proportional hazards model and Clinical significance.
Her work deals with themes such as Metastatic breast cancer, Chemotherapy, Adjuvant therapy and Hazard ratio, which intersect with Oncology. The Cancer study combines topics in areas such as Guideline and Radiation therapy. In the field of Surgery, her study on Mucositis overlaps with subjects such as Temsirolimus and Ridaforolimus.
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer. In her study, Gastroenterology is inextricably linked to Surgery, which falls within the broad field of Internal medicine. Her study of MammaPrint is a part of Breast cancer.
In her study, Everolimus is strongly linked to Letrozole, which falls under the umbrella field of Oncology. The study incorporates disciplines such as Hazard ratio and Intensive care medicine in addition to Cancer. Her study in Metastatic breast cancer is interdisciplinary in nature, drawing from both Phases of clinical research, Metastasis and Family medicine.
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. Fatima Cardoso studies MammaPrint, a branch of Breast cancer. She combines topics linked to Gene signature with her work on Internal medicine.
Her work on Adjuvant is typically connected to Pembrolizumab as part of general Oncology study, connecting several disciplines of science. Her Cancer research includes themes of Overall survival and Intensive care medicine. Her study looks at the intersection of Chemotherapy and topics like Early breast cancer with Anthracycline.
Her main research concerns Breast cancer, Internal medicine, Oncology, Cancer and Clinical trial. The concepts of her Breast cancer study are interwoven with issues in Quality of life, Disease, Health care and Family medicine. Her Disease study incorporates themes from Germline mutation and Epidemiology.
Her study in the field of Chemotherapy regimen also crosses realms of Pembrolizumab. Her Cancer research integrates issues from Adverse effect and Radiation therapy. Fatima Cardoso combines subjects such as Adjuvant and Neutropenia with her study of Metastatic breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
Christos Sotiriou;Pratyaksha Wirapati;Sherene Loi;Adrian Harris.
Journal of the National Cancer Institute (2006)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Senkus;S. Kyriakides;F. Penault-Llorca;P. Poortmans.
Annals of Oncology (2019)
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
Marc Buyse;Sherene Loi;Laura van't Veer;Giuseppe Viale.
Journal of the National Cancer Institute (2006)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets.
The New England Journal of Medicine (2016)
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,
Christine Desmedt;Fanny Piette;Sherene Loi;Yixin Wang.
Clinical Cancer Research (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja;F Cardoso;G de Castro;M Colozza.
British Journal of Cancer (2007)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum.
The Lancet (2011)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso;A. Costa;E. Senkus;M. Aapro.
Annals of Oncology (2017)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: